Consistent with these observations, Met expression in cultured PCa-derived cell lines was found to be inversely related to androgen receptor expression [8, 12], and phase II clinical trials of cabozantinib, a multikinase inhibitor with potent activity against Met, have reported frequent resolution of bone metastases in PCa patients with advanced disease [13–18]. Here, AR is linked to posterior cortical atrophy.